Saturday 17 October 2026
Export WAT’s income statement to Excel — free account
Waters Corporation
WAT Healthcare Diagnostics & Research
Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024. In the quarter to June 2026, revenue grew 113.4%, EPS fell 156.3%, free cash flow grew 750.0% and total debt rose 308.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
436.95
7.20
−1.62%
Follow WAT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
27.48 | 35.20 | 37.79 | 93.29 |
P/S ratio |
5.75 | 7.14 | 6.49 | 7.93 | |
P/FCF ratio |
29.63 | 44.53 | 105.62 | 100.47 | |
P/Operating CF |
95.44 | 137.36 | (8,153.66) | 183.24 | |
P/B ratio |
7.66 | 8.82 | 1.60 | 2.42 | |
Price to Tangible BV |
42.34 | 34.04 | 0.00 | 0.00 | |
EV/Sales |
5.90 | 7.25 | 7.65 | 8.87 | |
EV/EBITDA |
17.86 | 22.76 | 29.84 | 43.67 | |
EV/Operating CF |
25.18 | 35.19 | 74.07 | 74.93 | |
EV/FCF |
30.44 | 45.24 | 124.59 | 112.32 | |
Quick Ratio |
0.97 | 1.14 | 0.97 | 1.05 | |
Current Ratio |
1.53 | 1.73 | 1.79 | 1.86 | |
Net Debt/EBITDA |
1.99 | 1.11 | 27.46 | 20.22 | |
Debt/Assets |
19.48% | 18.65% | 19.79% | 19.74% | |
Debt/Equity |
0.41 | 0.37 | 0.32 | 0.32 | |
Asset Turnover |
0.66 | 0.66 | 0.26 | 0.32 | |
Operating CF/Net income |
1.26 | 0.73 | 0.04 | (1.48) | |
Capex/Depreciation |
(0.47) | (1.35) | (0.19) | (0.16) | |
Interest Coverage |
7.21 | 19.44 | (0.98) | (1.43) | |
Research and Development Expense of Revenue |
6.71% | 4.94% | 7.58% | 7.42% | |
Selling, General and Administrative Expense of Revenue |
26.78% | 26.18% | 30.54% | 24.62% | |
Intangible Assets out of Total Assets |
0.39 | 0.37 | 0.74 | 0.72 | |
Share Based Compensation of Revenue |
1.70% | 1.56% | 1.58% | 1.52% | |
Graham Net Nets |
(0.03) | (0.02) | (0.21) | (0.14) | |
Graham Number |
98.04 | 102.24 | 181.68 | 118.30 | |
Earnings Yield |
3.64% | 2.84% | 2.65% | 1.07% | |
Free Cash Flow Yield |
3.37% | 2.25% | 0.95% | 1.00% | |
Revenue per Share |
13.44 | 15.67 | 15.43 | 16.75 | |
Operating CF per Share |
3.14 | 2.77 | (0.04) | 2.05 | |
Capex per Share |
(0.42) | (1.20) | (0.47) | (0.49) | |
Free Cash Flow per Share |
2.73 | 1.57 | (0.51) | 1.56 | |
Cash per Share |
7.71 | 9.88 | 5.62 | 5.49 | |
Shareholders Equity per Share |
39.15 | 43.05 | 186.17 | 154.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
39.15 | 43.05 | 186.17 | 154.73 | |
Free Cash Flow |
162.23 | 93.37 | (42.00) | 153.00 | |
Working Capital |
667.90 | 909.00 | 1,791.00 | 2,066.00 | |
Capital Expenditures |
(24.77) | (71.19) | (39.00) | (48.00) | |
Net Current Asset Value |
(612.68) | (367.00) | (5,175.00) | (5,091.00) | |
EV/EBIT |
22.24 | 28.61 | 47.80 | 124.94 | |
Capex to Sales |
0.03 | 0.08 | 0.03 | 0.03 | |
Price to Operating Income |
21.65 | 28.16 | 40.53 | 111.75 | |
| Other line items | |||||
Average Receivables |
709.03 | 781.18 | 1,233.14 | 1,358.54 | |
Average Payables |
105.16 | 101.97 | 352.03 | 480.46 | |
Average Inventory |
545.97 | 524.63 | 1,003.75 | 958.88 | |
Average Assets |
4,687.09 | 4,815.40 | 14,561.29 | 14,734.54 | |
Average Common Equity |
1,966.90 | 2,195.25 | 8,627.20 | 8,677.41 |
Columns are period end dates